183 related articles for article (PubMed ID: 20881897)
1. Impact of operative blood loss on survival in invasive ductal adenocarcinoma of the pancreas.
Nagai S; Fujii T; Kodera Y; Kanda M; Sahin TT; Kanzaki A; Yamada S; Sugimoto H; Nomoto S; Takeda S; Morita S; Nakao A
Pancreas; 2011 Jan; 40(1):3-9. PubMed ID: 20881897
[TBL] [Abstract][Full Text] [Related]
2. Survival and prognosis of invasive intraductal papillary mucinous neoplasms of the pancreas: comparison with pancreatic ductal adenocarcinoma.
Woo SM; Ryu JK; Lee SH; Yoo JW; Park JK; Kim YT; Yoon YB
Pancreas; 2008 Jan; 36(1):50-5. PubMed ID: 18192881
[TBL] [Abstract][Full Text] [Related]
3. Prognosis of invasive intraductal papillary mucinous neoplasm.
Longnecker DS; Klöppel G
Pancreas; 2008 Oct; 37(3):333; author reply 333-4. PubMed ID: 18815559
[No Abstract] [Full Text] [Related]
4. Clinical significance of combined pancreas and portal vein resection in surgery for pancreatic adenocarcinoma.
Aramaki M; Matsumoto T; Etoh T; Ishio T; Himeno Y; Sasaki A; Yada K; Kawano K; Kitano S
Hepatogastroenterology; 2003; 50(49):263-6. PubMed ID: 12630036
[TBL] [Abstract][Full Text] [Related]
5. Retrospective evaluation of the influence of postoperative tumor marker status on survival and patterns of recurrence after surgery for pancreatic cancer based on RECIST guidelines.
Motoi F; Rikiyama T; Katayose Y; Egawa S; Unno M
Ann Surg Oncol; 2011 Feb; 18(2):371-9. PubMed ID: 20842460
[TBL] [Abstract][Full Text] [Related]
6. Invasive intraductal papillary-mucinous neoplasm of the pancreas: comparison with pancreatic ductal adenocarcinoma.
Murakami Y; Uemura K; Sudo T; Hayashidani Y; Hashimoto Y; Nakashima A; Sueda T
J Surg Oncol; 2009 Jul; 100(1):13-8. PubMed ID: 19384908
[TBL] [Abstract][Full Text] [Related]
7. [Results of surgical treatment in ampullary and pancreatic carcinoma and its prognostic parameters after R0-resection].
Ridwelski K; Meyer F; Schmidt U; Lippert H
Zentralbl Chir; 2005 Aug; 130(4):353-61. PubMed ID: 16103961
[TBL] [Abstract][Full Text] [Related]
8. The impact of obesity on outcomes following pancreatectomy for malignancy.
Benns M; Woodall C; Scoggins C; McMasters K; Martin R
Ann Surg Oncol; 2009 Sep; 16(9):2565-9. PubMed ID: 19557479
[TBL] [Abstract][Full Text] [Related]
9. Effects of perioperative red blood cell transfusion on disease recurrence and survival after pancreaticoduodenectomy for ductal adenocarcinoma.
Kneuertz PJ; Patel SH; Chu CK; Maithel SK; Sarmiento JM; Delman KA; Staley CA; Kooby DA
Ann Surg Oncol; 2011 May; 18(5):1327-34. PubMed ID: 21369744
[TBL] [Abstract][Full Text] [Related]
10. Long-term survival (5-20 years) after pancreatectomy for pancreatic ductal adenocarcinoma: a series of 30 patients collected from 3 institutions.
Adham M; Jaeck D; Le Borgne J; Oussoultzouglou E; Chenard-Neu MP; Mosnier JF; Scoazec JY; Mornex F; Partensky C
Pancreas; 2008 Nov; 37(4):352-7. PubMed ID: 18665012
[TBL] [Abstract][Full Text] [Related]
11. Pancreatectomy combined with superior mesenteric-portal vein resection: report of 32 cases.
Zhou GW; Wu WD; Xiao WD; Li HW; Peng CH
Hepatobiliary Pancreat Dis Int; 2005 Feb; 4(1):130-4. PubMed ID: 15730937
[TBL] [Abstract][Full Text] [Related]
12. Surgical outcome of intraductal papillary mucinous neoplasms of the pancreas.
Nakagohri T; Kinoshita T; Konishi M; Takahashi S; Gotohda N
Ann Surg Oncol; 2007 Nov; 14(11):3174-80. PubMed ID: 17694416
[TBL] [Abstract][Full Text] [Related]
13. L1 Cell adhesion molecule (L1CAM) expression at the cancer invasive front is a novel prognostic marker of pancreatic ductal adenocarcinoma.
Tsutsumi S; Morohashi S; Kudo Y; Akasaka H; Ogasawara H; Ono M; Takasugi K; Ishido K; Hakamada K; Kijima H
J Surg Oncol; 2011 Jun; 103(7):669-73. PubMed ID: 21360711
[TBL] [Abstract][Full Text] [Related]
14. Intrapancreatic nerve invasion as a predictor for recurrence after pancreaticoduodenectomy in patients with invasive ductal carcinoma of the pancreas.
Shimada K; Nara S; Esaki M; Sakamoto Y; Kosuge T; Hiraoka N
Pancreas; 2011 Apr; 40(3):464-8. PubMed ID: 21289526
[TBL] [Abstract][Full Text] [Related]
15. Expression of MAP4K4 is associated with worse prognosis in patients with stage II pancreatic ductal adenocarcinoma.
Liang JJ; Wang H; Rashid A; Tan TH; Hwang RF; Hamilton SR; Abbruzzese JL; Evans DB; Wang H
Clin Cancer Res; 2008 Nov; 14(21):7043-9. PubMed ID: 18981001
[TBL] [Abstract][Full Text] [Related]
16. Preoperative serum CA19-9 and dissected peripancreatic tissue margin as determiners of long-term survival in pancreatic cancer.
Waraya M; Yamashita K; Katagiri H; Ishii K; Takahashi Y; Furuta K; Watanabe M
Ann Surg Oncol; 2009 May; 16(5):1231-40. PubMed ID: 19263172
[TBL] [Abstract][Full Text] [Related]
17. Pattern of lymph node involvement and prognosis in pancreatic adenocarcinoma: direct lymph node invasion has similar survival to node-negative disease.
Pai RK; Beck AH; Mitchem J; Linehan DC; Chang DT; Norton JA; Pai RK
Am J Surg Pathol; 2011 Feb; 35(2):228-34. PubMed ID: 21263243
[TBL] [Abstract][Full Text] [Related]
18. Histologic characteristics enhance predictive value of American Joint Committee on Cancer staging in resectable pancreas cancer.
Helm J; Centeno BA; Coppola D; Melis M; Lloyd M; Park JY; Chen DT; Malafa MP
Cancer; 2009 Sep; 115(18):4080-9. PubMed ID: 19626671
[TBL] [Abstract][Full Text] [Related]
19. A and B blood group antigens in human pancreatic ductal adenocarcinomas.
Handra-Luca A
Oncology; 2013; 84(3):141-9. PubMed ID: 23257765
[TBL] [Abstract][Full Text] [Related]
20. Adverse oncologic effects of intraoperative transfusion during pancreatectomy for left-sided pancreatic cancer: the need for strict transfusion policy.
Hwang HK; Jung MJ; Lee SH; Kang CM; Lee WJ
J Hepatobiliary Pancreat Sci; 2016 Aug; 23(8):497-507. PubMed ID: 27295957
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]